Select Page
Exploring the impact of declining IgG4 levels post-vaccination on immunity and potential risks.
  • Dr. Philip McMillan discusses the significance of IgG4 levels in immunity post-vaccination. 0:03

  • Antibody levels post-infection typically average around 300 nanog per mil. 1:58

  • Concerns raised about significant rise in IgG4 levels post-vaccination. 2:26

  • IgG4, an unusual pattern in mRNA vaccination, poses potential risks to immune response. 4:06

Impact of IgG4 levels post-vaccination on immune response and viral replication.
  • IgG4 triggers immune system response, while IgG4 dampens it down. 4:30

  • Significant increase in IgG4 levels post mRNA vaccination. 6:00

  • Unexpected tolerance development towards Spike protein post-vaccination. 6:32

  • IgG4 interferes with virus cell entry but not replication. 7:05

  • High levels of viral dissemination observed in vaccinated cohorts. 7:32

  • Shift towards IgG4 antibodies post mRNA vaccination. 7:48

  • Increased IgG4 levels post-vaccination regardless of prior infection. 8:25

Implications of low IgG4 levels in viral infections and vaccine response.
  • Low levels of IgG4 in viral infections may lead to viral dissemination. 9:27

  • High levels of IgG4 may interfere with viral replication. 9:47

  • Tolerant antibodies suppressing the immune system raises concerns when they fall. 10:14

  • Risk-benefit analysis needed for vaccine interventions. 10:41

  • Importance of understanding disease presentation and vaccine uptake. 11:11

  • Data on antibody levels can provide insights into immunity trajectories. 11:48

  • Minimum IgG4 levels in normal infection compared to observed levels. 12:05

Concerns regarding declining IgG4 levels and potential hyperimmune response.
  • Antibody levels above 800 nanograms per mill considered protective. 12:47

  • Up to 93% in age group under 65 and 98% in over 65s had protective antibody levels. 12:54

  • Low vaccine booster uptake despite high antibody levels in certain age groups. 13:33

  • 30-40% of age group 16-24 have antibody levels between 179 to 800 nanograms per mill. 14:04

  • Concerns raised about majority having antibody levels above 6,000 in older age groups. 15:30

  • Shift from IgG4 to cellular response when levels fall may lead to hyperimmune response. 16:52

  • Potential risk of hyperimmune response due to lack of IgG4 and viral dissemination. 17:00

Potential consequences of declining IgG4 levels and the uncertainty surrounding further antibody boosting.
  • Concerns about immune response targeting various organs beyond the lung. 17:43

  • Uncertainty on the effectiveness of further antibody boostin. 18:17

  • Lack of clarity on managing potential inflammatory response. 19:01

  • Suggestion to consider alternative immune-suppressing treatment. 19:25

  • Critique of leadership’s handling of public health challenge. 19:47

  • Call for scientific preparation and readiness for potential adverse outcome. 20:03

  • Encouragement to stay informed and proactiv. 20:12